Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.

  title={Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.},
  author={W J Sandborn and S B Hanauer and P. R. Rutgeerts and Richard N Fedorak and Martin Luk{\'a}{\vs} and Donald G Macintosh and Remo Panaccione and Doerte Wolf and Jeffrey D. Kent and Barry Bittle and Jin Li and Paul F. Pollack},
  volume={56 9},
BACKGROUND Adalimumab induced clinical remission after four weeks in patients with active Crohn's disease in the CLASSIC I trial. OBJECTIVE To evaluate long term efficacy and safety of adalimumab maintenance therapy in Crohn's disease in a follow-on randomised controlled trial (CLASSIC II). METHODS In the preceding CLASSIC I trial, 299 patients with moderate to severe Crohn's disease naive to tumour necrosis factor antagonists received induction therapy with adalimumab 40 mg/20 mg, 80 mg/40… CONTINUE READING
Highly Influential
This paper has highly influenced 19 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
Recent Discussions
This paper has been referenced on Twitter 2 times over the past 90 days. VIEW TWEETS
329 Citations
31 References
Similar Papers


Publications citing this paper.
Showing 1-10 of 329 extracted citations


Publications referenced by this paper.
Showing 1-10 of 31 references

Tumour necrosis factor and Crohn's disease

  • SJ VanDeventer
  • Gut
  • 1997
Highly Influential
4 Excerpts

Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed

  • EC Keystone, AF Kavanaugh, JT Sharp
  • Ann Rheum Dis
  • 2004

Similar Papers

Loading similar papers…